|
Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648. |
|
|
Honoraria - Merck Serono; SERVIER |
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene |
Research Funding - Amgen; Incyte (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER |
|
|
Honoraria - Eisai; Lilly; SERVIER |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Pierre Fabre; Roche/Genentech; Sotio |
Research Funding - Janssen-Cilag (Inst); Lilly (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD |
|
|
Employment - Bristol-Myers Squibb/Celgene |
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene |
|
|
Employment - Bristol Myers Squibb |
Stock and Other Ownership Interests - Bristol Myers Squibb; GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |